Nominations for Members to Co-Chair the HHS Panel on the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children
The Department of Health and Human Services (HHS) Panel on the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children (or the Panel) is accepting nominations for scientific/clinical members with expertise in pediatric HIV infection and infectious diseases to co-chair the Panel.
Panel members critically evaluate new information and prepare guidelines revisions, and as co-chairs, work with assistance from the Executive Secretary to administer and direct Panel proceedings. The candidates shall be recognized experts in their areas of interest with a record of publications and presentations. The successful candidates shall serve a 4-year term beginning January 2020, with potential for reappointment. Because these are guidelines focused on the management of HIV-exposed and HIV-infected children within the United States, candidates should be from the United States.
The Panel is a Working Group of the Office of AIDS Research Advisory Council (OARAC) of the National Institutes of Health (NIH). The Panel is composed of approximately 30 members who are clinicians, researchers, academicians, and HHS representatives with expertise in the management of opportunistic infections and illnesses in HIV-exposed and HIV-infected children, pre-adolescents, and adolescents in the early stages of puberty.
The Panel meets biannually via teleconferencing to review and critically evaluate emerging scientific data relating to approvals of new drugs, vaccines, medical devices, or diagnostics; new information regarding indications or dosing; new safety or efficacy data; or other information that may affect the prevention and treatment of HIV-related opportunistic infections in children. Panel Co-Chairs work with the Executive Secretary to identify section authors for and edit revisions to the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children.
Panel members are not financially compensated for their time commitment.
The nomination should include a curriculum vitae and a letter of nomination or letter of interest with specific reference to how the nominee would contribute to the work of the Panel. Please submit all supporting documents to Claire Stevens, Clinical Info Guidelines Coordinator, at Claire.Stevens@icf.com. We are requesting that nominations be submitted by November 29, 2019.